[{"id":"ca926512-6064-4fa7-b79f-522281599998","acronym":"","url":"https://clinicaltrials.gov/study/NCT00049504","created_at":"2021-01-18T00:05:09.256Z","updated_at":"2024-07-02T16:37:22.043Z","phase":"Phase 2","brief_title":"Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer","source_id_and_acronym":"NCT00049504","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1","pipe":" | ","alterations":" CD8 expression • Chr del(5q) • CD4 expression","tags":["CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • Chr del(5q) • CD4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 01/01/2002","start_date":" 01/01/2002","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2017-05-17"}]